Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India

Curr Vasc Pharmacol. 2021 Nov 9. doi: 10.2174/1570161119666211109122231. Online ahead of print.ABSTRACTStroke is the second most common cause of death worldwide. The rates of stroke are increasing in less affluent countries predominantly because of a high prevalence of modifiable risk factors. The Lipid Association of India (LAI) has provided a risk stratification algorithm for patients with ischaemic stroke and recommended low density lipoprotein cholesterol (LDL-C) goals for those in a very high risk group and extreme risk group (category A) of
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Source Type: research

Related Links:

Publication date: Available online 11 September 2019Source: Journal of Clinical NeuroscienceAuthor(s): Yousheng Wu, Dan Lu, Anding XuAbstractThrombolysis-induced haemorrhagic transformation is the most challenging preventable complication in thrombolytic therapy. This condition is often associated with poor functional outcome and long-term disease burden. Statins, or 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, are controversially suggested to either increase or decrease the odds of better primary outcomes compared to treatment without statins after thrombolysis in patients or animals; statins are ...
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
AbstractIntroductionDrug utilization and outcomes research in multi-ethnic Asian stroke populations is lacking.ObjectivesOur objective was to examine temporal trends and predictors of drug utilization and outcomes in a multi-ethnic Asian stroke population.MethodsThis registry-based study included ischemic and hemorrhagic first-ever stroke patients hospitalized between 2009 and 2016. Utilization of medications included in-hospital thrombolytic agents, early antithrombotics (antiplatelets, anticoagulants) within 48  h of admission, and antithrombotics and statins at discharge. Outcomes analyzed were in-hospital all-caus...
Source: CNS Drugs - Category: Neurology Source Type: research
CONCLUSION: In patients with CAA, arterial hypertension should be tightly controlled. On the other hand, caution should be exercised in prescribing oral anticoagulants or platelet aggregation inhibitors for patients with CAA, or statins for patients who have already sustained a lobar ICH. PMID: 28179050 [PubMed - in process]
Source: Deutsches Arzteblatt International - Category: Journals (General) Tags: Dtsch Arztebl Int Source Type: research
More News: Brain | Cardiology | Cardiovascular | Cholesterol | Drugs & Pharmacology | Heart | Hemorrhagic Stroke | India Health | Ischemic Stroke | Neurology | Statin Therapy | Stroke | Thrombolytic Therapy | Thrombosis | Vytorin | Zetia